Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Definitive Healthcare (Nasdaq: DH) announced inducement awards for two newly hired senior leaders. The company granted 172,414 time-based restricted stock units (RSUs) to Kate Hastings, the new Chief Customer Officer, and 1,018,330 RSUs to Benjamin Graboske, the new EVP, Technology, Engineering and Chief Data Officer, both effective March 3, 2025.
The awards, granted under Nasdaq Listing Rule 5635(c)(4) and Definitive Healthcare's 2023 Inducement Plan, feature a vesting schedule where 25% vests initially (February 1, 2026 for Hastings; April 1, 2026 for Graboske), with the remainder vesting quarterly at 6.25% over three years, subject to continued employment.
Definitive Healthcare (Nasdaq: DH) ha annunciato premi di incentivazione per due nuovi leader senior assunti. L'azienda ha concesso 172.414 unità di azioni vincolate (RSU) basate sul tempo a Kate Hastings, la nuova Chief Customer Officer, e 1.018.330 RSU a Benjamin Graboske, il nuovo EVP, Tecnologia, Ingegneria e Chief Data Officer, entrambi con decorrenza dal 3 marzo 2025.
I premi, concessi secondo la Regola di Quotazione Nasdaq 5635(c)(4) e il Piano di Incentivazione 2023 di Definitive Healthcare, prevedono un programma di maturazione in cui il 25% matura inizialmente (1 febbraio 2026 per Hastings; 1 aprile 2026 per Graboske), con il resto che matura trimestralmente al 6,25% per tre anni, soggetto a continuazione dell'impiego.
Definitive Healthcare (Nasdaq: DH) anunció premios de incentivo para dos nuevos líderes senior contratados. La compañía otorgó 172,414 unidades de acciones restringidas (RSUs) basadas en el tiempo a Kate Hastings, la nueva Chief Customer Officer, y 1,018,330 RSUs a Benjamin Graboske, el nuevo EVP de Tecnología, Ingeniería y Chief Data Officer, ambos con efecto a partir del 3 de marzo de 2025.
Los premios, otorgados bajo la Regla de Cotización Nasdaq 5635(c)(4) y el Plan de Incentivos 2023 de Definitive Healthcare, presentan un calendario de adquisición donde el 25% se adquiere inicialmente (1 de febrero de 2026 para Hastings; 1 de abril de 2026 para Graboske), con el resto adquiriéndose trimestralmente al 6.25% durante tres años, sujeto a la continuación del empleo.
Definitive Healthcare (Nasdaq: DH)는 두 명의 신규 고위 임원에게 유인 보상을 발표했습니다. 이 회사는 새로운 고객 책임자인 Kate Hastings에게 172,414개의 시간 기반 제한 주식 단위(RSU)를, 새로운 EVP인 Benjamin Graboske에게 1,018,330개의 RSU를 부여했으며, 두 사람 모두 2025년 3월 3일부터 효력이 발생합니다.
이 보상은 Nasdaq 상장 규칙 5635(c)(4) 및 Definitive Healthcare의 2023 유인 계획에 따라 부여되며, 25%가 초기로 취득됩니다(2026년 2월 1일 Hastings; 2026년 4월 1일 Graboske), 나머지는 3년 동안 분기별로 6.25%씩 취득되며, 지속적인 고용이 조건입니다.
Definitive Healthcare (Nasdaq: DH) a annoncé des récompenses d'incitation pour deux nouveaux dirigeants seniors embauchés. L'entreprise a accordé 172 414 unités d'actions restreintes (RSU) basées sur le temps à Kate Hastings, la nouvelle Chief Customer Officer, et 1 018 330 RSU à Benjamin Graboske, le nouveau EVP, Technologie, Ingénierie et Chief Data Officer, tous deux prenant effet le 3 mars 2025.
Les récompenses, accordées en vertu de la Règle de Cotation Nasdaq 5635(c)(4) et du Plan d'Incitation 2023 de Definitive Healthcare, présentent un calendrier d'acquisition où 25% sont acquis initialement (1er février 2026 pour Hastings ; 1er avril 2026 pour Graboske), le reste étant acquis trimestriellement à 6,25% sur trois ans, sous réserve d'un emploi continu.
Definitive Healthcare (Nasdaq: DH) gab die Vergabe von Anreizprämien für zwei neu eingestellte Führungskräfte bekannt. Das Unternehmen gewährte 172.414 zeitbasierte Restricted Stock Units (RSUs) an Kate Hastings, die neue Chief Customer Officer, und 1.018.330 RSUs an Benjamin Graboske, den neuen EVP für Technologie, Ingenieurwesen und Chief Data Officer, beide mit Wirkung zum 3. März 2025.
Die Prämien, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) und dem Anreizplan 2023 von Definitive Healthcare gewährt wurden, umfassen einen Vesting-Plan, bei dem 25% zunächst fällig werden (1. Februar 2026 für Hastings; 1. April 2026 für Graboske), während der Rest vierteljährlich über drei Jahre mit 6,25% fällig wird, vorbehaltlich einer fortgesetzten Beschäftigung.
- Strategic executive hires in key positions (CCO and CDO)
- Substantial equity compensation aligning management interests with shareholders
- Potential future dilution from 1.19M new RSUs
FRAMINGHAM, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of two senior leaders, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare’s Board of Directors granted inducement awards. The Committee granted Kate Hastings, Definitive Healthcare’s new Chief Customer Officer an inducement award consisting of 172,414 time-based restricted stock units (“RSUs”) effective March 3, 2025 and granted Benjamin Graboske, Definitive Healthcare’s new EVP, Technology, Engineering and Chief Data Officer an inducement award consisting of 1,018,330 time-based RSUs, effective March 3, 2025. Each of these awards was individually negotiated and was granted as an inducement material to Ms. Hastings’ and Mr. Graboske’s respective commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).
Each of the awards is subject to the terms and conditions of Definitive Healthcare’s 2023 Inducement Plan (the “Plan”) and the terms and conditions of an applicable award agreement covering the grant.
Ms. Hastings’ RSUs will vest as follows, subject to Ms. Hastings’ continued employment through each such date: (i)
Mr. Graboske’s RSUs will vest as follows, subject to Mr. Graboske’s continued employment through each such date: (i)
About Definitive Healthcare
At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.
Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com
646-277-1251
Media Contact:
Bethany Swackhamer
bswackhamer@definitivehc.com
FAQ
How many RSUs did Definitive Healthcare (DH) grant to its new Chief Customer Officer?
What is the vesting schedule for Benjamin Graboske's RSU grant at DH?
When will Kate Hastings' RSUs begin vesting at Definitive Healthcare (DH)?
Under which regulatory rule were DH's inducement awards granted?
